MARKET

VIRX

VIRX

Viracta Therapeutics Inc
NASDAQ
0.8070
-0.0031
-0.38%
Closed 16:00 05/17 EDT
OPEN
0.8050
PREV CLOSE
0.8101
HIGH
0.8700
LOW
0.8050
VOLUME
70.76K
TURNOVER
0
52 WEEK HIGH
2.380
52 WEEK LOW
0.4300
MARKET CAP
31.69M
P/E (TTM)
-0.6525
1D
5D
1M
3M
1Y
5Y
Viracta Therapeutics Announces New Employment Inducement Grants
Viracta Therapeutics, Inc. Is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers. The company's Board of Directors granted Michael Faerm stock options to purchase 500,000 shares of common stock. Each option has an exercise price of $.
Barchart · 2d ago
Viracta Therapeutics Welcomes New CFO and Outlines Compensation
TipRanks · 5d ago
Viracta Therapeutics appoints Michael Faerm as CFO
Healthcare Viracta Therapeutics appoints Michael Faerm as CFO. Faerm has more than 25 years of experience in life sciences companies, equity research and investment banking. Viract a Therapeutic appoints Michael faerm as its CFO, effective immediately.
Seeking Alpha · 5d ago
VIRACTA THERAPEUTICS APPOINTS MICHAEL FAERM AS CHIEF FINANCIAL OFFICER
Reuters · 5d ago
Press Release: Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer. Mr. Faerm is a seasoned biotech executive with more than 25 years of experience in life sciences companies. Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers.
Dow Jones · 5d ago
Weekly Report: what happened at VIRX last week (0506-0510)?
Weekly Report · 6d ago
Viracta Therapeutics, Inc. - Form 10-Q - Condensed Consolidated Balance Sheets
Press release · 05/10 14:42
RBC Capital Keeps Their Buy Rating on Viracta Therapeutics (VIRX)
TipRanks · 05/10 10:49
More
About VIRX
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.

Webull offers Viracta Therapeutics Inc stock information, including NASDAQ: VIRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VIRX stock methods without spending real money on the virtual paper trading platform.